基于基因组增强的多变量预后模型用于国际队列中自然杀伤/T细胞淋巴瘤患者的生存预测
研究对260例自然杀伤/T细胞淋巴瘤(NKTCL)肿瘤进行二代测序,利用LASSO Cox回归构建由13个预后基因突变状态组成的基因组预后模型(GPM)。GPM与IPI、PINK、PINK-E风险特征弱相关,多变量分析显示GPM对无进展生存和总生存均独立显著。将GPM加入IPI、PINK、PINK-E后,Harrell's C指数显著提高。
要点
- GPM由13个预后基因的突变状态定义,与IPI、PINK、PINK-E风险特征弱相关。
- GPM对PFS独立显著(HR 3.73,95%CI 2.07-6.73;p<.001),对OS独立显著(HR 5.23,95%CI 2.57-10.65;p=.001)。
- GPM增强版IPI、PINK、PINK-E的Harrell's C指数在PFS和OS上均显著提高(p<.001,χ2检验)。
核心结论
- 基因组突变信息可指导NKTCL患者获得更好的预后分层。
研究设计与样本
- 回顾性队列研究,对260例NKTCL肿瘤进行二代测序,采用LASSO Cox回归训练基因组预后模型(GPM)。
主要发现
- GPM由13个预后基因的突变状态定义,与IPI、PINK、PINK-E的风险特征弱相关。
- Cox比例风险多变量回归显示,在校正上述指数已知风险特征后,GPM对PFS独立显著(HR 3.73,95%CI 2.07-6.73;p<.001)。
- Cox比例风险多变量回归显示,在校正上述指数已知风险特征后,GPM对OS独立显著(HR 5.23,95%CI 2.57-10.65;p=.001)。
- 对GPM突变样本额外赋予风险评分后,GPM增强版IPI、PINK、PINK-E的Harrell's C指数在PFS和OS上均显著提高(p<.001,χ2检验)。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
With lowering costs of sequencing and genetic profiling techniques, genetic drivers can now be detected readily in tumors but current prognostic models for Natural-killer/T cell lymphoma (NKTCL) have yet to fully leverage on them for prognosticating patients. Here, we used next-generation sequencing to sequence 260 NKTCL tumors, and trained a genomic prognostic model (GPM) with the genomic mutations and survival data from this retrospective cohort of patients using LASSO Cox regression. The GPM is defined by the mutational status of 13 prognostic genes and is weakly correlated with the risk-features in International Prognostic Index (IPI), Prognostic Index for Natural-Killer cell lymphoma (PINK), and PINK-Epstein-Barr virus (PINK-E). Cox-proportional hazard multivariate regression also showed that the new GPM is independent and significant for both progression-free survival (PFS, HR: 3.73, 95% CI 2.07-6.73; p < .001) and overall survival (OS, HR: 5.23, 95% CI 2.57-10.65; p = .001) with known risk-features of these indices. When we assign an additional risk-score to samples, which are mutant for the GPM, the Harrell's C-indices of GPM-augmented IPI, PINK, and PINK-E improved significantly (p < .001, χ2 test) for both PFS and OS. Thus, we report on how genomic mutational information could steer toward better prognostication of NKTCL patients.
引用
- Lim JQ, Huang D, Chan JY, et al. A genomic-augmented multivariate prognostic model for the survival of natural-killer/T-cell lymphoma patients from an international cohort. Am J Hematol. 2022. PMID: 35726449. doi:10.1002/ajh.26636
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。